While the promise of AbTCR-T cells to reduce the secretion of several inflammatory cytokines has exciting clinical potential, the discovery that tocilizumab, an anti-IL6R antibody, alleviates cytokine release syndrome (CRS) pathology, singles out IL-6 with particular clinical significance24–27. The gene discussed is IL6; the disease is congenital rubella syndrome.